Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Analysts at Oppenheimer lowered their Q1 2020 earnings per share estimates for shares of Aurinia Pharmaceuticals in a research report issued to clients and investors on Wednesday, December 4th, Zacks Investment Research reports. Oppenheimer analyst J. Kim now forecasts that the biotechnology company will post earnings per share of ($0.23) for the quarter, down from their previous estimate of ($0.20). Oppenheimer also issued estimates for Aurinia Pharmaceuticals’ Q2 2020 earnings at ($0.25) EPS, Q3 2020 earnings at ($0.28) EPS, Q4 2020 earnings at ($0.30) EPS, FY2020 earnings at ($1.05) EPS, FY2021 earnings at ($0.92) EPS and FY2022 earnings at ($0.03) EPS.
Other equities analysts have also issued research reports about the company. Bloom Burton reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. ValuEngine lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 5th. Cantor Fitzgerald increased their price target on Aurinia Pharmaceuticals from $24.00 to $30.00 in a research report on Thursday, December 5th. Royal Bank of Canada increased their price target on Aurinia Pharmaceuticals from $11.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. Finally, Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 28th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $19.46.
AUPH stock traded up $0.02 during trading hours on Monday, hitting $20.26. 2,279,367 shares of the stock traded hands, compared to its average volume of 7,147,630. The stock has a 50-day simple moving average of $13.19 and a 200 day simple moving average of $7.62. Aurinia Pharmaceuticals has a one year low of $3.52 and a one year high of $21.93. The company has a market cap of $2.17 billion, a P/E ratio of -26.66 and a beta of 1.27.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, November 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.05 million.
A number of institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp lifted its stake in Aurinia Pharmaceuticals by 4.6% in the 3rd quarter. Stifel Financial Corp now owns 43,011 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,902 shares in the last quarter. Virtu Financial LLC purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter worth about $122,000. Tower Research Capital LLC TRC lifted its stake in Aurinia Pharmaceuticals by 630.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 8,382 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 7,234 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Aurinia Pharmaceuticals by 42.9% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 3,000 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Aurinia Pharmaceuticals in the 3rd quarter worth about $246,000. 28.23% of the stock is owned by hedge funds and other institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
